Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 134, Issue 6, pp 559–561 | Cite as

Cardioprotective Effect of Trimetazidine during Thrombolytic Therapy in Patients with Acute Myocardial Infarction

  • T. Yu. Rebrova
  • T. V. Lasukova
  • S. A. Afanas'ev
  • V. A. Perchatkin
  • I. V. Maksimov
  • V. A. Markov
Article

Abstract

We studied the cardioprotective effect of anti-ischemic drug trimetazidine in the thrombolytic therapy of acute myocardial infarction. Trimetazidine (60 mg/day) effectively inhibits lipid peroxidation and moderates reperfusion damage to the myocardium assessed by ECG, QRS index of damaged heart, and release of creatine phosphokinase into circulation.

acute myocardial infarction thrombolytic reperfusion lipid peroxidation trimetazidine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    M. V. Bilenko, Ischemic and Reperfusion Regional Damage [in Russian], Moscow (1989).Google Scholar
  2. 2.
    I. V. Maksimov, Diagnostics and Treatment of Reperfusion Syndrome during Acute Myocardial Infarction, Abstract of Cand. Med. Sci. Dissertation, Tomsk (2000).Google Scholar
  3. 3.
    E. I. Chazov and M. Ya. Ruda, Kardiologiya, No. 2, 5–11 (1987).Google Scholar
  4. 4.
    E. I. Chazov and M. Ya. Ruda, Ibid., No. 11, 11–15 (1989).Google Scholar
  5. 5.
    J. Detry, P. Sellier, S. Pennaforte, et al., Br. J. Clin. Pharmacol., 37, 279–288 (1994).Google Scholar
  6. 6.
    R. Ferrari, C. Ceconi, S. Curello, et al., J. Cardiovasc. Pharmacol., 28, S18–S26 (1996).Google Scholar
  7. 7.
    P. Kantor, A. Lucien, R. Kozak., et al., Circ. Res., 17, 580–588 (2000).Google Scholar
  8. 8.
    G. Lopaschuk, Eur. Heart J. Suppl., 1, 2–39 (1999).Google Scholar
  9. 9.
    G. Lopaschuk, D. Belke, J. Gamble, et al., Biochim. Biophys. Acta, 1213, 263–276 (1994).Google Scholar
  10. 10.
    M. Oliver and I. Opie, Lancet, 343, 155–158 (1994).Google Scholar
  11. 11.
    P. Sellier, P. Audouin, B. Payen, et al., Eur. J. Clin. Pharmacol., 33, 205–207 (1987).Google Scholar
  12. 12.
    The EMIP-FRGROUP, Eur. Heart. J., 21, 1537–1546 (2000).Google Scholar
  13. 13.
    G. Wagner, C. Freye, S. Palmari, et al., Circulation., 65, 342–347 (1982).Google Scholar
  14. 14.
    Y. Yagi, M. Matsuda, and K. Yagi, Experientia, 32,No. 7, 905–906 (1976).Google Scholar

Copyright information

© Plenum Publishing Corporation 2002

Authors and Affiliations

  • T. Yu. Rebrova
    • 1
    • 2
    • 3
  • T. V. Lasukova
    • 1
    • 2
    • 3
  • S. A. Afanas'ev
    • 1
    • 2
    • 3
  • V. A. Perchatkin
    • 1
    • 2
    • 3
  • I. V. Maksimov
    • 1
    • 2
    • 3
  • V. A. Markov
    • 1
    • 2
    • 3
  1. 1.Laboratory of Molecular and Cell Pathology and Genetic DiagnosticsRussia
  2. 2.Department of Emergency CardiologyRussia
  3. 3.Siberian Division of the Russian Academy of Medical SciencesLaboratory of Experimental Cardiology, Institute of CardiologyTomsk

Personalised recommendations